Manel Merabet
Company: SKYMAB Biotherapeutics
Job title: Chief Development Officer
Seminars:
Next-Generation ADCs for GPCR-Expressing Tumors: Unlocking New Therapeutic Opportunities 4:30 pm
GPCRs as Emerging Targets: Understanding the role of GPCRs in oncogenic signaling and tumor progression Tumor-Specific GPCR Targeting: Designing ADCs with enhanced selectivity for tumorassociated GPCR isoforms Combination Strategies: Exploring synergistic effects of SKM-104 ADC with checkpoint inhibitors, chemotherapy, or radiotherapyRead more
day: Conference Day One
Fireside Chat: Examining the Future Possibilities of Modalities for GPCRTargeted Drugs to Become More Effective & Feasible 4:00 pm
How can we begin to develop orally available peptides? How do you turn a peptide starting point into a small molecule drug? What are the other modalities that can be employed to target GPCRs? Do some modalities lend themselves better to specific indications/GPCRs?Read more
day: Conference Day One
Progressing a GPR65-Targeted Drug to the Clinic to Treat Cancer 3:30 pm
Advancing to phase I/II clinical trials with a novel immune-oncology therapy What has been learned from GPCR clinical trials to drive therapeutic success and inform better trail designs? Addressing challenges in clinical trials through molecular-level discoveries to enable more precise targeting Read more
day: Conference Day Two
Chair’s Closing Remarks 4:30 pm
day: Conference Day Two